tiprankstipranks
Advertisement
Advertisement

GB:0MH6 Stock Latest News

RatingsBenjamin Jackson Reiterates Hold on Ipsen as Corabotase Data Show Limited Differentiation from Next‑Gen Neurotoxins
4d ago
PremiumCompany Announcements
Ipsen’s corabotase shows prolonged effect and high satisfaction in phase II glabellar lines trial
5d ago
Ipsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis
PremiumCompany Announcements
Ipsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis
2M ago
0MH6
Ipsen’s IPN10200 Phase 3 Aesthetics Trial: What Investors Should Watch
PremiumCompany Announcements
Ipsen’s IPN10200 Phase 3 Aesthetics Trial: What Investors Should Watch
3M ago
0MH6
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
PremiumCompany Announcements
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
3M ago
0MH6
Ipsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors
PremiumCompany AnnouncementsIpsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors
3M ago
0MH6
Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study
Premium
Company Announcements
Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study
3M ago
0MH6
Ipsen’s Tazemetostat Trial in Tough Lymphoma Group Withdrawn: What Investors Should Know
Premium
Company Announcements
Ipsen’s Tazemetostat Trial in Tough Lymphoma Group Withdrawn: What Investors Should Know
4M ago
0MH6
Ipsen’s CaboLife Study: Real-World Cancer Data That Could Shape Cabozantinib’s Market Future
PremiumCompany Announcements
Ipsen’s CaboLife Study: Real-World Cancer Data That Could Shape Cabozantinib’s Market Future
4M ago
0MH6
Ipsen’s New Study on Tazemetostat: A Potential Game-Changer for Follicular Lymphoma
PremiumCompany Announcements
Ipsen’s New Study on Tazemetostat: A Potential Game-Changer for Follicular Lymphoma
5M ago
0MH6
Ipsen’s Dysport® vs. Botox®: A Completed Study on Upper Limb Spasticity
PremiumCompany Announcements
Ipsen’s Dysport® vs. Botox®: A Completed Study on Upper Limb Spasticity
5M ago
0MH6
Ipsen’s Genetic Study on PFIC: A Potential Game-Changer for Liver Disorder Diagnosis
PremiumCompany Announcements
Ipsen’s Genetic Study on PFIC: A Potential Game-Changer for Liver Disorder Diagnosis
7M ago
0MH6
Ipsen’s New Study on IPN60300: A Potential Game-Changer for Advanced Tumours
PremiumCompany AnnouncementsIpsen’s New Study on IPN60300: A Potential Game-Changer for Advanced Tumours
7M ago
0MH6
Ipsen’s New Study on IPN01203: A Potential Game-Changer for Advanced Tumour Treatment
Premium
Company Announcements
Ipsen’s New Study on IPN01203: A Potential Game-Changer for Advanced Tumour Treatment
7M ago
0MH6
Ipsen’s New Study on Odevixibat: Long-term Insights for PFIC Treatment
Premium
Company Announcements
Ipsen’s New Study on Odevixibat: Long-term Insights for PFIC Treatment
8M ago
0MH6
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
PremiumCompany Announcements
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
9M ago
0MH6
Ipsen’s Real-World Study on Cabozantinib and Nivolumab: A Potential Game-Changer for RCC Treatment
PremiumCompany Announcements
Ipsen’s Real-World Study on Cabozantinib and Nivolumab: A Potential Game-Changer for RCC Treatment
9M ago
0MH6
Ipsen’s Innovative Approach to PBC: A Study on Itch and Sleep Patterns
PremiumCompany Announcements
Ipsen’s Innovative Approach to PBC: A Study on Itch and Sleep Patterns
9M ago
0MH6
Ipsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
PremiumCompany Announcements
Ipsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
9M ago
0MH6
Ipsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
PremiumCompany AnnouncementsIpsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
9M ago
0MH6
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
Premium
Company Announcements
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
9M ago
0MH6
Ipsen’s Phase II Osteosarcoma Study: A Potential Game Changer?
Premium
Company Announcements
Ipsen’s Phase II Osteosarcoma Study: A Potential Game Changer?
9M ago
0MH6

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >